On Tuesday, February 21, Walmart will be announcing its earnings forecast for the upcoming year. This is a highly anticipated event, as Walmart is one of the largest retailers in the world, and its performance often reflects broader trends in the global economy.
Walmart's most recent earnings report, released in November 2022, showed strong growth in e-commerce sales, which increased by 43% compared to the same quarter the previous year. However, the company also reported slower growth in physical store sales, with a 1.9% increase compared to the same quarter the previous year.
Investors will be looking closely at Walmart's earnings forecast to see how the company expects to perform in the coming year. With the ongoing COVID-19 pandemic continuing to impact the retail industry, it's likely that Walmart's e-commerce sales will remain strong, as consumers continue to do more of their shopping online. However, the company may continue to struggle with growth in physical stores, particularly as the pandemic has led to changes in consumer behavior.
Overall, Walmart's earnings forecast will be an important indicator of the health of the retail industry, as well as broader trends in the global economy. Investors and analysts will be paying close attention to the company's performance, looking for signs of continued growth and adaptation to the changing retail landscape.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where CVS declined for three days, in of 286 cases, the price declined further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on February 27, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on CVS as a result. In of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for CVS turned negative on February 28, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .
CVS moved below its 50-day moving average on February 28, 2024 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CVS crossed bearishly below the 50-day moving average on March 01, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CVS advanced for three days, in of 313 cases, the price rose further within the following month. The odds of a continued upward trend are .
CVS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 229 cases where CVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CVS's P/B Ratio (1.216) is slightly lower than the industry average of (3.070). CVS has a moderately low P/E Ratio (11.420) as compared to the industry average of (17.029). Projected Growth (PEG Ratio) (1.071) is also within normal values, averaging (1.055). CVS has a moderately high Dividend Yield (0.034) as compared to the industry average of (0.020). P/S Ratio (0.266) is also within normal values, averaging (0.646).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CVS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 68, placing this stock slightly better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
an integrated pharmacy health care provider
A.I.dvisor indicates that over the last year, CVS has been loosely correlated with ELV. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if CVS jumps, then ELV could also see price increases.